Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing

다국어 초록 (Multilingual Abstract)

Schizophrenia is a debilitating psychiatric disorder with a substantial socioeconomic and humanistic burden. Currently available treatment strategies mostly rely on antipsychotic drugs, which block dopaminergic effects in the mesolimbic pathway of the brain. Although antipsychotic drugs help relieve psychotic symptoms, a definitive cure for schizophrenia has yet to be achieved. Recent advances in neuroinflammation research suggest that proinflammatory processes in the brain could cause alterations in neurobehavioral development and increase vulnerability to schizophrenia. With a growing need for novel strategies in the treatment of schizophrenia, it would be meaningful to review the current evidence supporting the therapeutic potential of anti-inflammatory strategies. This review details the key findings of clinical trials that investigate the efficacy of anti-inflammatory agents as adjuvants to antipsychotic treatment. We further discuss the possibilities of repurposing anti-inflammatory agents and developing novel strategies for the treatment of schizophrenia.

참고문헌 (Reference)

1 Miyamoto S, "Treatments for schizophrenia : a critical review of pharmacology and mechanisms of action of antipsychotic drugs" 10 : 79-104, 2005

2 Müller N, "The role of inflammation in schizophrenia" 9 : 372-, 2015

3 Rotaru DC, "The role of glutamatergic inputs onto parvalbumin-positive interneurons : relevance for schizophrenia" 23 : 97-109, 2012

4 Farrar MA, "The molecular cell biology of interferon-gamma and its receptor" 11 : 571-611, 1993

5 Jonakait GM, "The effects of maternal inflammation on neuronal development : possible mechanisms" 25 : 415-425, 2007

6 Iaccarino HF, "The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood : Implications for schizophrenia" 150 : 392-397, 2013

7 Vevera J, "The effect of prolonged simvastatin application on serotonin uptake, membrane microviscosity and behavioral changes in the animal model" 158 : 112-120, 2016

8 Howes OD, "The dopamine hypothesis of schizophrenia : version III--the final common pathway" 35 : 549-562, 2009

9 Kerksick C, "The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress" 2 : 38-44, 2005

10 Corsello SM, "The Drug Repurposing Hub : a next-generation drug library and information resource" 23 : 405-408, 2017

11 Hashimoto K, "Targeting of NMDA receptors in new treatments for schizophrenia" 18 : 1049-1063, 2014

12 Ellman LM, "Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8" 121 : 46-54, 2010

13 Nair A, "Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation" 171 : 72-85, 2006

14 Ichim TE, "Stem cell therapy for autism" 5 : 30-, 2007

15 Zhang J, "Statins, autophagy and cancer metastasis" 45 : 745-752, 2013

16 Abdullah Bolu, "Serum Levels of High Sensitivity C-reactive Protein in Drug-naïve First-episode Psychosis and Acute Exacerbation of Schizophrenia" 대한정신약물학회 17 (17): 244-249, 2019

17 Tenn CC, "Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition" 180 : 366-376, 2005

18 Arevalo MA, "Selective oestrogen receptor modulators decrease the inflammatory response of glial cells" 24 : 183-190, 2012

19 Hirsch L, "Second-generation antipsychotics and metabolic side effects : a systematic review of population-based studies" 40 : 771-781, 2017

20 Larsson MK, "Repeated LPS injection induces distinct changes in the kynurenine pathway in mice" 41 : 2243-2255, 2016

21 Weickert T, "Reduction in peripheral c-reactive protein levels with canakinumab administration is related to reduced positive symptom severity in patients with schizophrenia and inflammation" 45 : S318-, 2019

22 Do KQ, "Redox dysregulation, neurodevelopment, and schizophrenia" 19 : 220-230, 2009

23 Ling Z, "Progressive dopamine neuron loss following supra-nigral lipopolysaccharide(LPS)infusion into rats exposed to LPS prenatally" 199 : 499-512, 2006

24 Koenig HL, "Progesterone synthesis and myelin formation by Schwann cells" 268 : 1500-1503, 1995

25 Brown AS, "Prenatal infection and schizophrenia : a review of epidemiologic and translational studies" 167 : 261-280, 2010

26 Brown AS, "Prenatal infection and cavum septum pellucidum in adult schizophrenia" 108 : 285-287, 2009

27 Bakos J, "Prenatal immune challenge affects growth, behavior, and brain dopamine in offspring" 1018 : 281-287, 2004

28 Urakubo A, "Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain" 47 : 27-36, 2001

29 Samuelsson AM, "Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A)dysregulation and impaired spatial learning" 290 : R1345-R1356, 2006

30 Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement" 151 : 264-269, 2009

31 Trépanier MO, "Postmortem evidence of cerebral inflammation in schizophrenia : a systematic review" 21 : 1009-1026, 2016

32 Pérez-Neri I, "Possible mechanisms of neurodegeneration in schizophrenia" 31 : 1279-1294, 2006

33 Romero E, "Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats : implications for the etiopathology of schizophrenia" 15 : 372-383, 2010

34 Bazan NG, "Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection" 10 : 136-141, 2007

35 Chalon S, "Omega-3 fatty acids and monoamine neurotransmission" 75 : 259-269, 2006

36 Brenhouse HC, "Nonsteroidal anti-inflammatory treatment prevents delayed effects of early life stress in rats" 70 : 434-440, 2011

37 Mellon SH, "Neurosteroid regulation of central nervous system development" 116 : 107-124, 2007

38 Doorduin J, "Neuroinflammation in schizophrenia-related psychosis : a PET study" 50 : 1801-1807, 2009

39 Monji A, "Neuroinflammation in schizophrenia especially focused on the role of microglia" 42 : 115-121, 2013

40 Sparkman NL, "Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress" 15 : 323-330, 2008

41 Müller N, "Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders" 6 : 1017-1038, 2006

42 Romero E, "Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics" 32 : 1791-1804, 2007

43 Gozes I, "NAP(davunetide)provides functional and structural neuroprotection" 17 : 1040-1044, 2011

44 Farokhnia M, "N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia : a randomized, double-blind, placebo-controlled study" 36 : 185-192, 2013

45 Berk M, "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial" 64 : 361-368, 2008

46 Bloomfield PS, "Microglial activity in people at ultra high risk of psychosis and in schizophrenia : an [(11)C]PBR28 PET brain imaging study" 173 : 44-52, 2016

47 Frank MG, "Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses" 21 : 47-59, 2007

48 Block ML, "Microglia and inflammation-mediated neurodegeneration : multiple triggers with a common mechanism" 76 : 77-98, 2005

49 van Berckel BN, "Microglia activation in recent-onset schizophrenia : a quantitative(R)-[11C]PK11195 positron emission tomography study" 64 : 820-822, 2008

50 Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia : clinical status and antipsychotic effects" 70 : 663-671, 2011

51 Uccelli A, "Mesenchymal stem cells in health and disease" 8 : 726-736, 2008

52 Joyce N, "Mesenchymal stem cells for the treatment of neurodegenerative disease" 5 : 933-946, 2010

53 Le Blanc K, "Mesenchymal stem cells : progress toward promise" 7 : 36-45, 2005

54 Lauren S. Sherman, "Mesenchymal stem cell therapies in brain disease" Elsevier BV 95 : 111-119, 2019

55 Guginski G, "Mechanisms involved in the antinociception caused by ethanolic extract obtained from the leaves of Melissa officinalis(lemon balm)in mice" 93 : 10-16, 2009

56 Gilmore JH, "Maternal poly I : C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat" 159 : 106-112, 2005

57 Shi L, "Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring" 23 : 297-302, 2003

58 Fatemi SH, "Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring : implications for genesis of neurodevelopmental disorders" 99 : 56-70, 2008

59 Zuckerman L, "Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring" 39 : 311-323, 2005

60 Smith SE, "Maternal immune activation alters fetal brain development through interleukin-6" 27 : 10695-10702, 2007

61 Buka SL, "Maternal cytokine levels during pregnancy and adult psychosis" 15 : 411-420, 2001

62 Gayle DA, "Maternal LPS induces cytokines in the amniotic fluid and corticotropin releasing hormone in the fetal rat brain" 286 : R1024-R1029, 2004

63 Chen SF, "Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury" 81 : 288-298, 2007

64 Giuliani M, "Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation" 6 : e19988-, 2011

65 Rosendo AB, "Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals" 33 : 244-250, 2010

66 Parrott JM, "Kynurenine 3-monooxygenase : an influential mediator of neuropathology" 6 : 116-, 2015

67 Siniscalco D, "Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice" 67 : 655-669, 2010

68 Behrens MM, "Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia" 28 : 13957-13966, 2008

69 Zalcman S, "Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats" 847 : 276-283, 1999

70 Zalcman S, "Interleukin-2 and-6 induce behavioral-activating effects in mice" 811 : 111-121, 1998

71 Furukawa H, "Interleukin-1, but not stress, stimulates glucocorticoid output during early postnatal life in mice" 840 : 117-122, 1998

72 Chen G, "Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats : a potential neuroprotective mechanism of N-acetylcysteine" 2008 : 716458-, 2008

73 Pandurangi AK, "Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia" 2019

74 Howes OD, "Inflammation and the neural di athesis-stress hypothesis of schizophrenia : a reconceptualization" 7 : e1024-, 2017

75 Khandaker GM, "Inflammation and immunity in schizophrenia : implications for pathophysiology and treatment" 2 : 258-270, 2015

76 Ehrenreich H, "Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin" 12 : 206-220, 2007

77 Beggs KJ, "Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons" 15 : 711-721, 2006

78 van Kesteren CF, "Immune involvement in the pathogenesis of schizophrenia : a meta-analysis on postmortem brain studies" 7 : e1075-, 2017

79 Patterson PH, "Immune involvement in schizophrenia and autism : etiology, pathology and animal models" 204 : 313-321, 2009

80 Millier A, "Humanistic burden in schizophrenia : a literature review" 54 : 85-93, 2014

81 Wang Q, "High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex : possible involvement of endothelial nitric oxide synthase" 144 : 933-939, 2005

82 Wang Q, "High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities : the association with the up-regulation of NMDA receptor binding in the rat brain" 216 : 132-138, 2009

83 Dold M, "Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders" 1 : CD009831-, 2015

84 Janáky R, "Glutathione modulates the N-methyl-D-aspartate receptor-activated calcium influx into cultured rat cerebellar granule cells" 156 : 153-157, 1993

85 Charlson FJ, "Global epidemiology and burden of schizophrenia : findings from the global burden of disease study 2016" 44 : 1195-1203, 2018

86 Brown AS, "Exposure to prenatal infection and risk of schizophrenia" 2 : 63-, 2011

87 Zhou D, "Exposure to physical and psychological stressors elevates plasma interleukin 6 : relationship to the activation of hypothalamic-pituitary-adrenal axis" 133 : 2523-2530, 1993

88 Kulkarni J, "Estrogen in severe mental illness : a potential new treatment approach" 65 : 955-960, 2008

89 Fink G, "Estrogen control of central neurotransmission : effect on mood, mental state, and memory" 16 : 325-344, 1996

90 Sirén AL, "Erythropoietin--a novel concept for neuroprotection" 251 : 179-184, 2001

91 Stone TW, "Endogenous kynurenines as targets for drug discovery and development" 1 : 609-620, 2002

92 Brown AS, "Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring" 161 : 889-895, 2004

93 Allswede DM, "Elevated maternal cytokine levels at birth and risk for psychosis in adult offspring" 172 : 41-45, 2016

94 Boksa P, "Effects of prenatal infection on brain development and behavior : a review of findings from animal models" 24 : 881-897, 2010

95 Cui K, "Effects of prenatal immune activation on hippocampal neurogenesis in the rat" 113 : 288-297, 2009

96 Asanuma Y, "Effects of C-reactive protein and homocysteine on cytokine production : modulation by pravastatin" 1 : 14-22, 2008

97 Javitt DC, "Effect of the neuroprotective peptide davunetide(AL-108)on cognition and functional capacity in schizophrenia" 136 : 25-31, 2012

98 Csontos C, "Effect of N-acetylcysteine treatment on oxidative stress and inflammation after severe burn" 38 : 428-437, 2012

99 Wang S, "Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide" 1265 : 196-204, 2009

100 Meyer U, "Developmental neuroinflammation and schizophrenia" 42 : 20-34, 2013

101 Cai Z, "Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration" 47 : 64-72, 2000

102 Lewis DA, "Cortical inhibitory neurons and schizophrenia" 6 : 312-324, 2005

103 Klausberger T, "Complementary roles of cholecystokininand parvalbumin-expressing GABAergic neurons in hippocampal network oscillations" 25 : 9782-9793, 2005

104 Ellman LM, "Cognitive functioning prior to the onset of psychosis : the role of fetal exposure to serologically determined influenza infection" 65 : 1040-1047, 2009

105 Wang Q, "Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain" 154 : 1100-1106, 2008

106 Vevera J, "Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission" 133 : 197-203, 2005

107 Müller N, "Celecoxib treatment in an early stage of schizophrenia : results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment" 121 : 118-124, 2010

108 Rapaport MH, "Celecoxib augmentation of continuously ill patients with schizophrenia" 57 : 1594-1596, 2005

109 Akhondzadeh S, "Celecoxib as adjunctive therapy in schizophrenia : a double-blind, randomized and placebo-controlled trial" 90 : 179-185, 2007

110 El-Sayed El-Sisi A, "Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia" 82 : 425-431, 2016

111 Brown AS, "Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia" 49 : 473-486, 2001

112 Müller N, "Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia" 159 : 1029-1034, 2002

113 Siniscalco D, "Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?" 2012 : 480289-, 2012

114 Brown AS, "Association of maternal genital and reproductive infections with verbal memory and motor deficits in adult schizophrenia" 188 : 179-186, 2011

115 Attari A, "Aspirin inclusion in antipsychotic treatment on severity of symptoms in schizophrenia : a randimized clinical trial" 11 : e5848-, 2017

116 Foussias G, "Antipsychotics and schizophrenia : from efficacy and effectiveness to clinical decision-making" 55 : 117-125, 2010

117 Singer P, "Anti-inflammatory properties of omega-3 fatty acids in critical illness : novel mechanisms and an integrative perspective" 34 : 1580-1592, 2008

118 Miller BJ, "An open-label, pilot trial of adjunctive tocilizumab in schizophrenia" 77 : 275-276, 2016

119 Millan MJ, "Altering the course of schizophrenia : progress and perspectives" 15 : 485-515, 2016

120 Laan W, "Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders : results from a randomized, double-blind, placebo-controlled trial" 71 : 520-527, 2010

121 Cho M, "Adjunctive use of anti-inflammatory drugs for schizophrenia : a meta-analytic investigation of randomized controlled trials" 53 : 742-759, 2019

122 Shen H, "Adjunctive therapy with statins in schizophrenia patients : a meta-analysis and implications" 262 : 84-93, 2018

123 Grüber L, "Adjunctive recombinant human interferon gamma-1b for treatment-resistant schizophrenia in 2 patients" 75 : 1266-1267, 2014

124 Wehring HJ, "Adjunctive minocycline in clozapine-treated patients with schizophrenia : analyzing the effects of minocycline on clozapine plasma levels" 89 : 73-80, 2017

125 Xiang YQ, "Adjunctive minocycline for schizophrenia : a meta-analysis of randomized controlled trials" 27 : 8-18, 2017

126 Keller WR, "A review of anti-inflammatory agents for symptoms of schizophrenia" 27 : 337-342, 2013

127 Girgis RR, "A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia" 43 : 1317-1323, 2018

128 Peesa JP, "A perspective review on role of novel NSAID prodrugs in the management of acute inflammation" 5 : 364-381, 2016